GenSight Biologics S.A. (EPA: SIGHT)

Market Cap	36.74M
Revenue (ttm)	1.98M
Net Income (ttm)	-20.11M
Shares Out	115.16M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,125
Open	0.310
Previous Close	0.314
Day's Range	0.310 - 0.324
52-Week Range	0.280 - 0.598
Beta	2.30
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated N...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 16
• Stock Exchange: Euronext Paris
• Ticker Symbol: SIGHT

Financial Performance

In 2023, GenSight Biologics's revenue was 2.96 million, a decrease of -39.08% compared to the previous year's 4.87 million. Losses were -26.22 million, -5.09% less than in 2022.